Tag: Antibody Drug Conjugates

ADCs Pipeline

With fourteen approved drugs and several drug candidates being evaluated under different stages of development, antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics. The success of this relatively novel class of therapeutics is attributed to the ability of lead molecules to specifically identify and eliminate disease associated cells /

Antibody drug conjugates (ADCs) are an upcoming class of targeted therapeutic agents that have garnered the attention of pharmaceutical companies, and academic / research institutions across the world. Fundamentally, these complex biotherapeutic entities represent the combination of the target specificity of an antibody and the therapeutic features of a chemotherapy / cytotoxic drug. Such conjugates

Antibody-drug conjugates (ADCs) are an upcoming class of targeted therapeutic agents that have captured the attention of both large and small pharmaceutical companies, and academic / research institutions from all across the world. Fundamentally, these complex biotherapeutic entities demonstrate the combination of target specificity of an antibody and therapeutic features of a chemotherapy / cytotoxic

Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates to be recognized as potent therapies (ADC therapy) targeting a wide range of indications, including solid tumors and hematological malignancies. ADC therapy is an engineered therapy comprised of

Antibody-Drug Conjugates (ADCs) have captured the attention of both large and small pharmaceutical companies, and academic / research institutions, engaged in the ADC contract manufacturing market. For the past few years, several failures of clinical trials were blamed for the lack of interest of some companies in this therapeutic approach. However, after a decade-long dribble

On October 31, 2019, Daiichi Sankyo and Sarah Cannon Research Institute announced the dosing of the first patient in a first-in-human phase 1/2 study (NCT04145622) evaluating DS-7300. What is DS-7300? DS-7300 is an investigational B7-H3 targeting antibody-drug conjugate (ADC). What is B7-H3? It is a Type I transmembrane protein belonging to the B7 family, which includes immune

Last week, the eyes of all the key stakeholders in the Antibody Drug Conjugates (ADCs) Therapeutics space were on the developments happening in San Diego, California, at the 6th World ADC Awards.  The awards were meant to recognize the companies that are driving innovation in the field of ADCs Therapeutics. With six approved and marketed

Global Antibody Drug Conjugates ADC market is expanding and is estimated to be around USD 7.72 billion in 2023. The compound annual growth rate of ADC market is estimated to be 9.50% in the coming decade. Roots Analysis has been publishing multiple articles and key insights pack for ADC market growing potential to keep the